Copernicus Capital Management, LLC
- SEC CIK
- 0001694620
- Latest filing
- Nov 15, 2021
Holdings in Q1 2021
Holdings as of Mar 31, 2021, filed May 17, 2021. Long positions only.
- Positions
- 14
- No 13F data for Q4 2020
- Portfolio value
- $6.19M
- No 13F data for Q4 2020
Livermore's 13F data starts with Q1 2021, so this quarter has no previous quarter to compare with and changes are not shown.
| Security | Class | Shares | Value | % of portfolio | Share change | Action | History |
|---|---|---|---|---|---|---|---|
| BMRNBiomarin Pharmaceutical Inc | COM | 10,000 | $755.0K | 12.2% | – | – | History |
| REGNRegeneron Pharmaceuticals, Inc. | COM | 1,500 | $710.0K | 11.5% | – | – | History |
| FATEFate Therapeutics Inc | COM | 8,000 | $660.0K | 10.7% | – | – | History |
| ABBVAbbVie Inc. | Stock | 6,000 | $649.0K | 10.5% | – | – | History |
| VRTXVertex Pharmaceuticals Inc | Stock | 3,000 | $645.0K | 10.4% | – | – | History |
| RVMDRevolution Medicines, Inc. | COM | 10,000 | $459.0K | 7.4% | – | – | History |
| RCKTRocket Pharmaceuticals, Inc. | COM | 8,000 | $355.0K | 5.7% | – | – | History |
| GRTSGritstone bio, Inc. | COM | 37,000 | $349.0K | 5.6% | – | – | History |
| TGTXTG Therapeutics, Inc. | COM | 7,000 | $337.0K | 5.4% | – | – | History |
| ARDXArdelyx, Inc. | COM | 50,000 | $331.0K | 5.3% | – | – | History |
| RCUSArcus Biosciences, Inc. | COM | 10,000 | $281.0K | 4.5% | – | – | History |
| BCELAtreca, Inc. | CL A COM | 18,000 | $276.0K | 4.5% | – | – | History |
| TDOCTeladoc Health, Inc. | COM | 1,500 | $273.0K | 4.4% | – | – | History |
| ORTXOrchard Therapeutics plc | ADS | 15,000 | $109.0K | 1.8% | – | – | History |